M. Tunon De Lara (Bordeaux, France)
Montelukast can improve isolated nocturnal hypoxemia in stable COPD patients with positive reversibility test
B. Sposato, M. G. Migliorini, A. Ricci, S. Mariotta, C. Franco (Grosseto, Rome, Italy)
|  |
Exposure-response relationship for nebulized arformoterol in subjects with COPD
G. Maier, J. Kharidia, J. Hanrahan, R. Hsu, D. Jaworowicz, B. Cirincione, J. Owen, T. Grasela (Marlborough, Buffalo, United States Of America)
| |
Population pharmacokinetics of nebulized arformoterol in subjects with COPD
G. Maier, J. Kharidia, J. Hanrahan, R. Hsu, D. Jaworowicz, B. Cirincione, J. Owen, T. Grasela (Marlborough, Buffalo, United States Of America)
| |
Arformoterol in COPD: safety results from two pooled phase 3 trials
J. P. Hanrahan, E. Kerwin, H. Cheng, D. R. Grogan, R. A. Baumgartner (Marlborough, Medford, United States Of America)
| |
Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response
M. R. Refini, G. Ciarleglio, M. G. Pieroni, E. Vlad, P. Sestini (Siena, Italy)
| |
Uric acid, oxidative stress and inhaled steroids in stable chronic obstructive pulmonary disease
O. Lorenzo, J. Abreu, C. Hernández, P. Abreu, N. Lorenzo (La Laguna, Spain)
| |
Effect of suplementary dietary antioxidants in COPD patients
J. A. Ros-Lucas, C. Soto, M. D. Sanchez-Caro, B. Fernandez-Suarez, B. Cerda, J. Guardiola, F. J. Ruiz Lopez, M. Loremzo-Cruz, J. C. Espin, F. Sanchez-Gascon (Murcia, Spain)
| |
Increased oxidative stress in patients with chronic obstructive pulmonary disease (COPD) as measured by redox status of plasma coenzyme Q10
H. Wada, S. I. Hagiwara, E. Saitoh, R. Ieki, T. Okamura, T. Ota, M. Iguchi, T. Kodaka, T. Koishi, Y. Yamamoto, H. Goto (Tokyo, Tochigi, Shizuoka, Japan)
| |
Inhaler device plays an important role for the patients‘ QOL to be improved by switching from short-acting anticholinergics to once-daily bronchodilator tiotropium in COPD
N. Chohnabayashi, N. Nishimura, N. Uchiyama, H. Ueda, H. Ono, R. Sugiura, J. Kizu, K. Watanabe, T. Inoue (Tokyo, Japan)
| |
Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together
C. F. Vogelmeier, S. A. Harari, K. Fonay, J. Beier, T. Overend, D. Till, S. Stenglein, V. Oldani (Marburg, Wiesbaden, Nuernberg, Germany; Milan, Origgio, Italy; Sopron, Hungary; Horsham, United Kingdom)
| |
Anti-oxidant effects of erdosteine in current smokers with mild COPD
R. W. Dal Negro, M. Visconti, C. Micheletto, S. Tognella (Bussolengo, Italy)
| |
The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD
S. Kanda, K. Fujimoto, M. Yasuo, K. Urushihata, K. Kubo (Matsumoto, Japan)
| |
Tiotropium added to theophylline improves lung function in patients with chronic obstructive pulmonary disease rapidly, compared to theophylline alone
T. Kawayama, M. Ichiki, M. Kinoshita, T. Koga, H. Aizawa (Kurume, Japan)
| |
Inhaled corticosteroids are over prescribed in patients with COPD, attending hospital
J. Evans, K. E. Lewis (Llanelli, United Kingdom)
| |
Effects of long-acting bronchodilators on changes of inspiratory capacity by hyperventilation in patients with chronic obstructive pulmonary disease
Y. Eguchi, K. Hirata, T. Yoshikawa, H. Kamoi, H. Kanazawa, S. Fujimoto (Osaka, Japan)
| |
Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance
B. Burian, B. A. Nadler, A. Storka, V. Petkov, L. H. Block (Vienna, Austria)
| |
Budesonide/formoterol significantly improves lung function and reduces exacerbations in both smokers and ex-smokers with COPD
D. M. G. Halpin, S. Peterson (Exeter, United Kingdom; Lund, Sweden)
| |
Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients
H. Arievich, A. Potena, K. Fonay, C. F. Vogelmeier, T. Overend, J. Smith, S. Hedgecock, S. Stenglein (Berlin, Marburg, Nuernberg, Germany; Ferrara, Italy; Sopron, Hungary; Horsham, United Kingdom)
| |
Aerosol characterization of alpha-1 antitrypsin after nebulization with eFlow®, a novel vibrating membrane nebulizer
M. Tservistas, E. Bitterle, M. Keller, S. Bauer (Munich, Germany; Rehovot, Israel)
| |
Efficacy in COPD patients of tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) compared to HandiHaler® (HH)
J. A. van Noord, P. J. G. Cornelissen, J. L. Aumann, J. Platz, A. Mueller, C. Fogarty (Heerlen, Alkmaar, Netherlands; Hasselt, Belgium; Biberach a/d Riss, Germany; Spartanburg, United States Of America)
| |